Chemours Stock News

Comerica Bank lessened its stake in shares of The Chemours Company (NYSE:CC) by 2.0% during the second quarter, Holdings Channel.com reports. The firm owned 92,748 shares of the specialty chemicals companys stock after selling 1,934 shares during the period. Comerica Banks holdings in Chemours were worth $2,912,000 as of its most recent SEC filing. Several []

There is value in stocks trading at a discount to their 2022 estimates.

CC, NVMI, OLN, and ARCB made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 22, 2021.

PAG, CC, RM, and SPH made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 22, 2021.

Chemours (CC) benefits from strong end-market demand and its cost-reduction and pricing actions.

Stopping the unlicensed manufacture, marketing, and sales of HFO-1234yf refrigerants protects innovation and customers WILMINGTON, Del. , Nov. 22, 2021 /PRNewswire/ -- On November 12, 2021 , The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials and Chemical Solutions, announced that it files a second patent infringement lawsuit in Japan against AGC, Inc. This action reaffirms Chemours'' commitment to vigorously defend its intellectual property and investment in Opteon low global warming potential (GWP) refrigerants and builds on its on-going efforts to stop the unlicensed manufacture, marketing, and sales of Opteon HFO-1234yf (R-1234yf) refrigerant by all legal means wherever that activity occurs around the world. The second lawsuit was filed on November 12, 2021 with the Tokyo District Court Civil Divisio (case number 2021(Wa)29388). It alleges infringement of Chemours'' patents covering HFO-1234yf product compositions.

Chemours (NYSE:CC) updated its FY 2021 earnings guidance on Thursday. The company provided EPS guidance of $3.930-$4.130 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.670. The company issued revenue guidance of -. Separately, Royal Bank of Canada upped their price objective on Chemours from $40.00 to $45.00 and gave the []

Chemours' (CC) new disinfectant product, Glyclean D, promises to be an environmental-friendly household cleaner.

UCLA Law School Professor Stephen Bainbridge recently commented Vice Chancellor Glasscock''s recent memorandum opinion in In re The Chemours Co. Deriv. Litig., (Del. Ch. Case No. 2020-0786-SG, Nov. 1, 2021). Professor Bainbridge notes that the Chemours case provides some guidance on how to boards of directors should make valuation decisions in determining whether a dividend may be paid under Delaware law. He notes that state corporate laws generally does not require adherence to Generally By: Allen Matkins

TGLS, CC, and DDS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 16, 2021.

A safe strategy with huge potential.

TGLS, CC, and NMRK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 11, 2021.

BLDR, FLGT, MRBK, CC, and NMRK have been added to the Zacks Rank #1 (Strong Buy) List on November 11th.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

The Chemours Company (CC) CEO Mark Newman on Q3 2021 Results - Earnings Call Transcript